Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Selling, General & Admin	4.92	4.76	6.18	3.87	1.34
Research & Development	4.3	3.55	5.6	2.96	2.27
Operating Expenses	9.22	8.31	11.78	6.83	3.61
Operating Income	-9.22	-8.31	-11.78	-6.83	-3.61
Interest Expense	-0.38	-0.15	-	-	-0.01
Interest & Investment Income	0.26	0.25	0.09	0.01	0
Other Non Operating Income (Expenses)	0.86	0.01	-0.04	-0	-26.63
Pretax Income	-8.48	-8.2	-11.73	-6.83	-30.25
Net Income	-8.48	-8.2	-11.73	-6.83	-30.25
Preferred Dividends & Other Adjustments	-	-	-	-	8.21
Net Income to Common	-8.48	-8.2	-11.73	-6.83	-38.46
Shares Outstanding (Basic)	34	26	25	23	14
Shares Outstanding (Diluted)	34	26	25	23	14
Shares Change (YoY)	30.97%	2.98%	7.41%	71.49%	13.44%
EPS (Basic)	-0.25	-0.32	-0.47	-0.29	-2.83
EPS (Diluted)	-0.25	-0.32	-0.47	-0.29	-2.83
EBIT	-9.22	-8.31	-11.78	-6.83	-3.61

Updated Sep 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q